Determinación de la susceptibilidad a la vancomicina en cepas de Staphylococcus aureus meticilino-resistente (SaRm) aisladas en un hospital de tercer nivel de complejidad de medellín mediante varias pruebas de sensibilidad antimicrobiana

Ana M. Ocampo; Lina M. Echeverri; J. Natalia Jiménez

doi:10.17533/udea.hm.15060

Authors

Ana M. Ocampo University of Antioquia
Lina M. Echeverri University Hospital of San Vicente Foundation
J. Natalia Jiménez University of Antioquia

DOI:

https://doi.org/10.17533/udea.hm.15060

Keywords:

antimicrobial susceptibility testing, methicillin-resistant staphylococcus aureus (MRSA), resistance, vancomycin

Abstract

BACKGROUND

Vancomycin has been the most effective antibiotic against infections caused by methicillin resistant Staphylococcus aureus (MRSA). To date there are no reports of Intermediate Vancomycin-Intermediate Staphylococcus aureus (VISA) or Vancomycin-Resistant Staphylococcus aureus (VRSA) in Colombia; however there is a high prevalence of MRSA and increased vancomycin use, which are contributing factors to their emergence. Additionally, routine methods used for detection of these strains such as automated and disc diffusion have limitations.

OBJECTIVE

To evaluate vancomycin susceptibility in a collection of MRSA strains isolated from patients between 2008-2010 in a University hospital of Medellin.

MATERIALS AND METHODS

150 MRSA isolates were selected. The vancomycin minimum inhibitory concentration (MIC) was performed by Vitek-2 and Etest. Additionally, vancomycin screen agar plates were employed.

RESULTS

All of the isolates tested were susceptible to vancomycin, however, differences between the evaluated methods were observed: the 59.3% of the isolates (n=89) showed an MIC 1 ug/mL by Etest, whereas by Vitek2, only the 22% (n = 33) of the isolates had this value.

CONCLUSIONS

We found a significant number of isolates with an MIC 1 ug/mL, which have been associated with increased risk of treatment failure. These results show the relevance of permanent surveillance of antibiotic resistance, to achieve the establishment of appropriate control strategies.

|Abstract

= 353 veces | PDF (ESPAÑOL (ESPAÑA))

= 1124 veces|

Downloads

Download data is not yet available.

Author Biographies

Ana M. Ocampo, University of Antioquia

Bacterial Molecular Epidemiology Line. Molecular Microbiology Group, University of Antioquia. Research Group in Basic and Applied Microbiology, MICROBA.

J. Natalia Jiménez, University of Antioquia

Bacterial Molecular Epidemiology Line. Molecular Microbiology Group, University of Antioquia. Research Group in Basic and Applied Microbiology, MICROBA.

References

Aires de Sousa M, de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunol Med Microbiol. 2004;40(2):101-11. Epub 2004/03/26.

Deleo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the geno-mics era. J Clin Invest. 2009;119(9):2464-74. Epub 2009/09/05.

Moreillon P, Ai-que Y.Staphylococcus aureus (Including Staphylococcal Toxic Shock). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7 ed: Elsevier; 2005. p. 2321-48.

Deleo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect dis Clin North Am. 2009;23(1):17-34. Epub 2009/01/13.

Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46 Suppl 5:S350-9. Epub 2008/05/28.

Tristan A, Ferry T, Durand G, Dauwalder O, Bes M, Lina G, et al. Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2007;65 Suppl 2:105-9. Epub 2007/08/19.

Chopra I. Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures. Expert Rev Anti Infect Ther. 2003;1(1):45-55. Epub 2004/10/16

de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol. 2007;10(5):428-35. Epub 2007/10/09.

Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265-73. Epub 2003/05/03.

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763-71. Epub 2007/10/18.

Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010;375(9725):1557-68. Epub 2010/03/09.

Conly JM, Johnston BL. VISA, hetero-VISA and VRSA: The end of the vancomycin era? Can J Infect Dis. 2002;13(5):282-4. Epub 2007/12/27.

Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Mi-crobiol. 2009;7(9):629-41. Epub 2009/08/15.

Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureusWorking Group. N Engl J Med. 1999;340(7):493-501. Epub 1999/02/18.

Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7(2):327-32. Epub 2001/04/11.

Tenover FC. Implications of vancomycin-resistant Staphylococcus aureus. J Hosp Infect. 1999;43 Suppl:S3-7. Epub 2000/02/05.

Huang LY WC, Jang TN and Yeh HL. Nephrotoxicity of Vancomycin and Teicoplanin Alone and in Combination with an Aminoglycoside. Taiwan Pharm J. 2007;59(1):1-8.

Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001;1(3):147-55. Epub 2002/03/02.

Fitzgibbon MM, Rossney AS, O’Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureusisolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol. 2007;45(10):3263-9. Epub 2007/08/10.

Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wi-lkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46(5):668-74. Epub 2008/02/09.

Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillinresistant Staphylococcus aureus lineages. Emerg Infect Dis. 2004;10(5):855-7. Epub 2004/06/18.

Voss A, Mouton JW, van Elzakker EP, Hendrix RG, Goessens W, Kluytmans JA, et al. A multi-center blinded study on the e!ciency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimi-crob. 2007;6:9. Epub 2007/09/26.

Hageman JC, Patel JB, Carey RC, Tenover FC. McDonald LC. Investigation and control of vancomicin-intermediate an -resistant Staphylococcus aureus: A Guide for health Departments and infection Control personnel. Atlanta, GA. 2006. Available from: www.cdc.gov/ncidod/dhqp/ar_visa_prevention.html.

Hawkey PM. Low-level glycopeptide resistance in methicillin-resistant Staphylococcus aureus and how to test it. Clin Microbiol Infect. 2009;15 Suppl 7:2-9. Epub 2009/12/03.

Behera. Erroneous reporting of vamcomycin susceptibility for Staphylococcus spp. by vitek software ver-sion 2.01. Jpn JInfect Dis. 2009;62:298-9.

Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, et al. Comparison of method-speci"c vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32(5):378-85. Epub 2008/08/15.

Swenson JM, Anderson KF, Lonsway DR, Thomp-son A, McAllister SK, Limbago BM, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Sta-phylococcus aureus. J Clin Microbiol. 2009;47(7):2013-7. Epub 2009/05/08.

Boletín GREBO Número 2. Grupo para el control de la resistencia bacteriana en Bogotá, Editor. 2009. Avai-lable from: http://www.grebo.org/upload/eve200001.pdf.

GERMEN. Per!es de sensibilidad a antibióticos Sta-phylococcus aureus 2007-2009. Grupo para el Estudio de la Resistencia a Antibióticos de Medellín. 2009. Available from: http://www.grupogermen.org/pdf/Staphylococcus.pdf.

Arias CA, Reyes J, Zuniga M, Cortes L, Cruz C, Rico CL, et al. Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Co-lombian hospitals, 2001-2002. J Antimicrob Chemo-ther. 2003;51(1):59-68. Epub 2002/12/21.

Contreras GAG, CA, and Leal AL.Staphylococcus au-reus resistente a la vancomicina: una nueva amenaza. Infectio. 2005;9(2):91-9.

Guzman-Blanco M, Mejia C, Isturiz R, Alvarez C, Ba-vestrello L, Gotuzzo E, et al. Epidemiology of methi-cillin-resistant Staphylococcus aureus (MRSA) in Latin America. Int J Antimicrob Agents. 2009;34(4):304-8. Epub 2009/07/25.

Rodríguez CA aVO.Staphylococcus aureus resistente a vancomicina. Biomédica. 2005;25:575-87.

Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for Staphylococcus aureus en-terotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. J Clin Microbiol. 2000;38(3):1032-5. Epub 2000/03/04.

CLSI Performance Standards for Antimicrobial susceptibility testing: Twentieth Informational Su-pplement. CLSI document M100-S20. Wayne, PA: Cli-nical and Laboratory Standards Institiute; 2010.

Ruef C. Epidemiology and clinical impact of glyco-peptide resistance in Staphylococcus aureus. Infec-tion. 2004;32(6):315-27. Epub 2004/12/15.

Srinivasan A, Dick JD, Perl TM. Vancomycin resistan-ce in staphylococci. Clin Microbiol Rev. 2002;15(3):430-8. Epub 2002/07/05.

Wang G, Hindler JF, Ward KW, Bruckner DA. Increa-sed vancomycin MICs for Staphylococcus aureus clini-cal isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44(11):3883-6. Epub 2006/09/08.

Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococ-cus aureus (VISA), vancomycin-susceptible clinical me-thicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60(4):788-94. Epub 2007/07/12.

Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect. 2010;60(2):140-5. Epub 2009/12/08.

van Hal SJ, Lodise TP, Paterson DL. The clinical signi"cance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755-71. Epub 2012/02/04.

Lodise TP, Graves J, Evans A, Gra!under E, Helmec-ke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with me-thicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemo-ther. 2008;52(9):3315-20. Epub 2008/07/02.

Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. In!uence of vancomycin minimum inhibitory concentration on the treatment of methi-cillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200. Epub 2008/01/04.

Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-inter-mediate and heterogeneous vancomycin-interme-diate strains: resistance mechanisms, laboratory de-tection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99-139. Epub 2010/01/13.

Nadarajah R, Post LR, Liu C, Miller SA, Sahm DF, Brooks GF. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sen-sititre System and the MicroScan System. Compa-rison with results from the conventional Etest and CLSI standardized MIC methods. Am J Clin Pathol. 2010;133(6):844-8. Epub 2010/05/18.

Burnham CA, Weber CJ, Dunne WM, Jr. Novel screening agar for detection of vancomycin-non-susceptible Staphylococcus aureus. J Clin Microbiol. 2010;48(3):949-51. Epub 2010/01/22.